TF
NVCR icon

TimeScale Financial’s NovoCure NVCR Stock Holding History

TimeScale Financial’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$5.81K Buy
+140
New +$8.69K ﹤0.01% 414

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

TimeScale Financial's NVCR Position: Q2 2023 in Review

TimeScale Financial opened a new position in NovoCure (NVCR) in Q2 2023: 140 shares worth $5.81K. The stake represents ﹤0.01% of the portfolio and ranks #414 among its holdings.

267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • TimeScale Financial held 140 shares of NovoCure worth $5.81K as of Q2 2023.
  • NovoCure was a new TimeScale Financial position in Q2 2023.
  • NovoCure made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #414 holding.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.